NBA Head Coach Receiving Treatment for Hodgkin's

Flip Saunders, head coach and president of operations of the National Basketball Association's Minnesota Timberwolves announced on Tuesday that he has Hodgkin's lymphoma.

[Photo credit: Carlos Gonzalez, Star Tribune]

Saunders, who is being treated at the Mayo Clinic in Rochester, MN., also announced that he learned of the diagnosis several weeks ago and is in fact eight weeks into treatment for what his doctors say is a “very treatable and curable form” of the disease.

“I don’t think it will impact him at all,” Team owner Glen Taylor said, noting that Saunders hasn't missed any meetings. “We can work around his schedule.”

Saunders has been overwhelmed with the outpouring of support he has received since making the announcement, tweeting that "the goodness of people should never be questioned.”

Saunders, 60, is set to begin his second season coaching the Timberwolves in the fall.

“I am taking it step by step and day by day to understand how to best manage this process,” he said. “I am attacking this with the same passion I do everything in my life, knowing this is a serious issue. I also know that God has prepared me for this battle.”

Source: Minneapolis Tribune

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap